ERBB2 and breast cancer: The PHILA study (NCT03863223) aimed to compare the efficacy of first-line treatment with docetaxel and trastuzumab in combination with either pyrotinib or placebo in metastatic HER2-positive breast cancer, enrolling 590 patients, including 297 in the pyrotinib group.